)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Initiator Pharma
Initiator Pharma (INIT) investor relations material
Initiator Pharma Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary8 May, 2026
Executive summary
Strategic focus shifted entirely to pudafensine, discontinuing IP2018 development after Q1.
Phase IIa clinical trial for pudafensine in vulvodynia progressing well, with topline results expected by end of 2026.
European patent granted for pudafensine in Female Sexual Dysfunction, strengthening IP position.
Financial highlights
No revenue generated in Q1 2026.
Operating loss of TDKK 11,432 in Q1 2026, up from TDKK 2,653 in Q1 2025, mainly due to increased R&D costs for the vulvodynia trial.
Net loss after tax was TDKK 11,551 in Q1 2026, compared to TDKK 2,653 in Q1 2025.
Cash and cash equivalents at March 31, 2026 were TDKK 19,803, down from TDKK 26,245 at year-end 2025.
Cash flow from operations was TDKK -11,813 in Q1 2026, reflecting increased clinical trial activity.
Outlook and guidance
Focus for 2026 is completion of the vulvodynia Phase IIa study and reporting topline data.
Current resources, including undrawn convertible facility, expected to fund operations through completion of the vulvodynia study and into 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Initiator Pharma
- Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data due in late 2024.INIT
DNB Carnegie Healthcare Seminar 202620 Mar 2026 - Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026.INITStora Aktiedagarna 202611 Mar 2026
- Phase IIa vulvodynia trial underway, strong IP, and solid financing position for 2026.INITQ4 202520 Feb 2026
- Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health.INITInvesting in Life Science 202516 Dec 2025
- Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets.INITQ3 202521 Nov 2025
- First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market.INITLife Science Summit 202520 Nov 2025
- Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses.INITQ2 202522 Aug 2025
- Reduced losses and strong clinical progress for pudafensine mark Q3 2024 for Initiator Pharma.INITQ3 202413 Jun 2025
- Reduced losses, new patents, and clinical progress position Initiator Pharma for future growth.INITQ2 202413 Jun 2025
Next Initiator Pharma earnings date
Q2 202621 Aug, 2026
Initiator Pharma
Next Initiator Pharma earnings date
Q2 202621 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage